Keratoconus (KC) is the most common ectatic corneal disease, with clinical findings that include discomfort, visual disturbance and possible blindness if left untreated. KC affects approximately 1:400 to 1:2000 people worldwide, including both males and females. The aetiology and onset of KC remains a puzzle and as a result, the ability to treat or reverse the disease is hampered. Sex hormones are known to play a role in the maintenance of the structure and integrity of the human cornea. Hormone levels have been reported to alter corneal thickness, curvature, and sensitivity during different times of menstrual cycle. Surprisingly, the role of sex hormones in corneal diseases and KC has been largely neglected. Prolactin-induced protein, known to be regulated by sex hormones, is a new KC biomarker that has been recently proposed. Studies herein discuss the role of sex hormones as a control mechanism for KC onset and progression and evidence supporting the view that prolactin-induced protein is an important hormonally regulated biomarker in KC is discussed.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder showcasing an interaction between genetic predisposition and environmental risks. This usually involves the coaction of a mixture of cell types associated with abnormal wound healing, leading to structural distortion and loss of gas exchange function. IPF bears fatal prognosis due to respiratory failure, revealing a median survival of approximately 2 to 3 years. This review showcases the ongoing progress in understanding the complex pathophysiology of IPF and it highlights the latest potential clinical treatments. In IPF, various components of the immune system, particularly clotting cascade and shortened telomeres, are highly involved in disease pathobiology and progression. This review also illustrates two US Food and Drug Administration (FDA)-approved drugs, nintedanib (OFEV, Boehringer Ingelheim, Ingelheim am Rhein, Germany) and pirfenidone (Esbriet, Roche, Basel, Switzerland), that slow IPF progression, but unfortunately neither drug can reverse the course of the disease. Although the mechanisms underlying IPF remain poorly understood, this review unveils the past and current advances that encourage the detection of new IPF pathogenic pathways and the development of effective treatment methods for the near future.

We show by whole genome sequence analysis that loss of RNase H2 activity increases loss of heterozygosity (LOH) in Saccharomyces cerevisiae diploid strains harboring the pol2-M644G allele encoding a mutant version of DNA polymerase e that increases ribonucleotide incorporation. This led us to analyze the effects of loss of RNase H2 on LOH and on nonallelic homologous recombination (NAHR) in mutant diploid strains with deletions of genes encoding RNase H2 subunits (rnh201D, rnh202D, and rnh203D), topoisomerase 1 (TOP1D), and/or carrying mutant alleles of DNA polymerases e, a, and d. We observed an 7-fold elevation of the LOH rate in RNase H2 mutants encoding wild-type DNA polymerases. Strains carrying the pol2-M644G allele displayed a 7-fold elevation in the LOH rate, and synergistic 23-fold elevation in combination with rnh201D. In comparison, strains carrying the pol2-M644L mutation that decreases ribonucleotide incorporation displayed lower LOH rates. The LOH rate was not elevated in strains carrying the pol1-L868M or pol3-L612M alleles that result in increased incorporation of ribonucleotides during DNA synthesis by polymerases a and d, respectively. A similar trend was observed in an NAHR assay, albeit with smaller phenotypic differentials. The ribonucleotide-mediated increases in the LOH and NAHR rates were strongly dependent on TOP1. These data add to recent reports on the asymmetric mutagenicity of ribonucleotides caused by topoisomerase 1 processing of ribonucleotides incorporated during DNA replication. KEYWORDS LOH; NAHR; genome stability; recombination; ribonucleotides T HE replicative DNA polymerases of Saccharomyces cerevisiae, DNA polymerases a (Pol a), d (Pol d), and e (Pol e), frequently incorporate ribonucleotides into DNA both in vitro and during nuclear DNA replication in vivo (Nick McElhinny et al. 2010a,b;Williams and Kunkel 2014;Williams et al. 2015). These ribonucleotides are efficiently removed when RNase H2 incises the DNA backbone containing a ribonucleotide to initiate ribonucleotide excision repair (RER) (Nick McElhinny et al. 2010a;Sparks et al. 2012). When the RNH201 gene that encodes the catalytic subunit of RNase H2 (Cerritelli and Crouch 2009) is deleted, RER is defective and many unrepaired ribonucleotides remain in the genome. A subset of these unrepaired ribonucleotides can be removed when topoisomerase 1 (TOP1) incises a DNA backbone containing a ribonucleotide . However, TOP1 incision creates nicks with unligatable ends and elicits several RNA-DNA damage phenotypes, including slow growth, activation of the genome integrity checkpoint and altered progression through the cell cycle, sensitivity to the replication inhibitor hydroxyurea (HU), and strongly elevated rates for deletion of 2-5 bp from low-complexity DNA sequences (Nick McElhinny et al. 2010a;Clark et al. 2011;Kim et al. 2011). These effects are elicited primarily by ribonucleotides incorporated by Pol e, but not by ribonucleotides incorporated by Pol a or Pol d (Williams et al. 2015). Loss of RNase H2 is a...

No abstract

Currently, over 10 million people worldwide are affected by corneal blindness. Corneal trauma and disease can cause irreversible distortions to the normal structure and physiology of the cornea often leading to corneal transplantation. However, donors are in short supply and risk of rejection is an ever-present concern. Although significant progress has been made in recent years, the wound healing cascade remains complex and not fully understood. Tissue engineering and regenerative medicine are currently at the apex of investigation in the pursuit of novel corneal therapeutics. This review uniquely integrates the clinical and cellular aspects of both corneal trauma and disease and provides a comprehensive view of the most recent findings and potential therapeutics aimed at restoring corneal homeostasis.